Literature DB >> 26935749

Clinical outcomes in the surgical treatment of idiopathic normal pressure hydrocephalus.

Richard Shaw1, Emma Everingham2, Neil Mahant3, Erica Jacobson4, Brian Owler5.   

Abstract

Idiopathic normal pressure hydrocephalus (INPH) is a syndrome of gait disturbance, dementia and urinary incontinence. Outcomes after ventriculoperitoneal shunting for INPH are variable due to a lack of reliable, quantitative outcome data and inconsistent methods of selecting shunt candidates. The aim of this retrospective cohort study was to assess objective and quantitative clinical outcomes of ventriculoperitoneal shunting for INPH. From 2008 to 2013, consecutive patients diagnosed with INPH based on clinical and radiological criteria were included in this single-centre study. All patients received programmable-valve ventriculoperitoneal shunts. Outcome measures were assessed at baseline, 3, 6 and 12months post-operatively. Outcomes included gait time and scores on the Unified Parkinson's Disease Rating Scale part III (UPDRS-III), the Addenbrooke's Cognitive Examination Revised (ACE-R) and the Mini-Mental State Examination (MMSE). Thresholds for improvements were set a priori as ⩾20% decrease in gait time, ⩾10point decrease in UPDRS-III score, ⩾5point increase in ACE-R score and ⩾2point increase in MMSE score at last follow-up. The proportion of patients improving varied between measures, being gait time (60%), UPDRS-III (69%), MMSE (63%), and ACE-R (56%). Overall, improvement in at least one outcome measure was observed in 85% of patients and 38% improved in gait time, UPDRS-III score and cognitive scores. Only 15% of patients experienced no improvement on any measure. This study demonstrates that the majority of INPH patients can sustain improvements in multiple symptoms up to 12months after shunting.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Normal pressure hydrocephalus; Outcomes; Shunting

Mesh:

Year:  2016        PMID: 26935749     DOI: 10.1016/j.jocn.2015.10.044

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  5 in total

1.  Quantitative imaging features predict spinal tap response in normal pressure hydrocephalus.

Authors:  Eyal Lotan; Brianna E Damadian; Henry Rusinek; Megan Griffin; Benjamin Ades-Aron; Ning Lu; James Golomb; Ajax E George
Journal:  Neuroradiology       Date:  2021-08-20       Impact factor: 2.804

2.  Guidelines for Management of Idiopathic Normal Pressure Hydrocephalus (Third Edition): Endorsed by the Japanese Society of Normal Pressure Hydrocephalus.

Authors:  Madoka Nakajima; Shigeki Yamada; Masakazu Miyajima; Kazunari Ishii; Nagato Kuriyama; Hiroaki Kazui; Hideki Kanemoto; Takashi Suehiro; Kenji Yoshiyama; Masahiro Kameda; Yoshinaga Kajimoto; Mitsuhito Mase; Hisayuki Murai; Daisuke Kita; Teruo Kimura; Naoyuki Samejima; Takahiko Tokuda; Mitsunobu Kaijima; Chihiro Akiba; Kaito Kawamura; Masamichi Atsuchi; Yoshihumi Hirata; Mitsunori Matsumae; Makoto Sasaki; Fumio Yamashita; Shigeki Aoki; Ryusuke Irie; Hiroji Miyake; Takeo Kato; Etsuro Mori; Masatsune Ishikawa; Isao Date; Hajime Arai
Journal:  Neurol Med Chir (Tokyo)       Date:  2021-01-15       Impact factor: 1.742

3.  Long-Term Prognosis of Cognitive Function in Patients With Idiopathic Normal Pressure Hydrocephalus After Shunt Surgery.

Authors:  Akihiro Kambara; Yoshinaga Kajimoto; Ryokichi Yagi; Naokado Ikeda; Motomasa Furuse; Naosuke Nonoguchi; Shinji Kawabata; Toshihiko Kuroiwa; Kenji Kuroda; Shohei Tsuji; Ryuichi Saura; Masahiko Wanibuchi
Journal:  Front Aging Neurosci       Date:  2021-01-20       Impact factor: 5.750

4.  Physical Capacity and Activity in Patients With Idiopathic Normal Pressure Hydrocephalus.

Authors:  Johanna Rydja; Lena Kollén; Martin Ulander; Mats Tullberg; Fredrik Lundin
Journal:  Front Neurol       Date:  2022-03-28       Impact factor: 4.003

5.  Clinical Outcomes of Shunting in Normal Pressure Hydrocephalus: A Multicenter Prospective Observational Study.

Authors:  Sokol Trungu; Antonio Scollato; Luca Ricciardi; Stefano Forcato; Filippo Maria Polli; Massimo Miscusi; Antonino Raco
Journal:  J Clin Med       Date:  2022-02-26       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.